ライフサイエンスコーパス: argatroban

1 ifibatide); or DTIs (r-hirudin, bivalirudin, argatroban).

2 outcome were lower in the patients receiving argatroban.

3 ing which was not impacted by bivalirudin or argatroban.

4 t thrombin inhibitors (DTIs) bivalirudin and argatroban.

5 fluorogenic substrate, and (iv) titration of argatroban (0-1.5 microg/mL) into plugs and measurement

6 Argatroban (0.5-2.2 ug/kg/min) and high-dose IV immunogl

7 Argatroban 2 microg x kg x min, adjusted to achieve acti

8 age was similar in the three groups (4% with argatroban, 3% with eptifibatide, and 2% with placebo).

9 nt (fondaparinux = 133, danaparoid = 59, and argatroban = 47) for suspected or confirmed HIT.

10 core: eptifibatide, 6.47; 95% CI, 5.79-7.15; argatroban, 5.35; 95% CI, 4.13-6.58; placebo, 6.68; 95%

11 tal of 514 patients were assigned to receive argatroban (59 patients), eptifibatide (227 patients), o

12 fied Rankin scale scores were 5.2+/-3.7 with argatroban, 6.3+/-3.2 with eptifibatide, and 6.8+/-3.0 w

13 Intravenous infusion of argatroban, a direct thrombin inhibitor, alleviated neur

14 study evaluating the efficacy and safety of argatroban, a direct thrombin inhibitor, as anticoagulan

15 44) received 2 microgram. kg(-1). min(-1) IV argatroban, adjusted to maintain the activated partial t

16 Argatroban administration significantly reduced hepatic

17 y of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide (an

18 urred in 37.5% of heparin, 32.0% of low-dose argatroban and 25.5% of high-dose argatroban patients (p

19 onal costs, fondaparinux prevailed over both argatroban and bivalirudin in terms of cost ($151 vs $12

20 inux has similar effectiveness and safety as argatroban and danaparoid in patients with suspected HIT

21 Argatroban and high-dose IV immunoglobulin along with ma

22 Argatroban and lepirudin are well studied and approved d

23 direct thrombin inhibitors (DTI; lepirudin, argatroban) and danaparoid.

24 Argatroban anticoagulation, compared with historical con

25 ice were given the direct thrombin inhibitor argatroban approximately 15 mg/kg/day or its vehicle via

26 Argatroban, as compared with heparin, appears to enhance

27 e conducted a cost-effectiveness analysis of argatroban, bivalirudin, and fondaparinux for the treatm

28 rin agents such as fondaparinux, danaparoid, argatroban, bivalirudin, or one of the new direct-acting

29 as effectively inhibited with danaparoid and argatroban but also by heparin.

30 switching to a nonheparin anticoagulant (ie, argatroban, danaparoid) upon clinical suspicion.

31 performance in heparinized mice; bivalirudin/argatroban did not affect exercise tolerance.

32 Argatroban did not significantly impact hepatic steatosi

33 Analysis of the argatroban dose-response data with a competitive inhibit

34 m onset were assigned to receive intravenous argatroban, eptifibatide, or placebo within 75 minutes a

35 nearly a half, whereas doubling the dose of argatroban from its IC50 would decrease coagulation acti

36 Mortality at 90 days was higher in the argatroban group (24%) and the eptifibatide group (12%)

37 in the placebo group [83%]; 17 of 27 in the argatroban group [63%], and 82 of 98 in the eptifibatide

38 bectomy (110 in the placebo group, 31 in the argatroban group, and 113 in the eptifibatide group).

39 mbectomy: 94 in the placebo group, 27 in the argatroban group, and 98 in the eptifibatide group.

40 In the argatroban group, baseline platelet counts were signific

41 c analyses demonstrated that permeation with argatroban had no significant effects on clot structure.

42 In vitro and in vivo studies have shown that argatroban has advantages over heparin for the inhibitio

43 The antithrombotic activity of argatroban has been quantified in fibrin clot permeation

44 Hirudin and argatroban have found their niche for the treatment of p

45 lowing attenuation of thrombin generation by argatroban in a serum-transfer nephrotoxic model identif

46 to heparin, low-dose argatroban or high-dose argatroban in addition to TPA.

47 were hemorrhagic (one per group, none during argatroban infusion); 30 (86%) were present at or within

48 m was developed to titrate an anticoagulant (argatroban) into blood samples and to measure the clotti

49 clot permeation system have also shown that argatroban is a potent inhibitor of clot-bound thrombin,

50 We conclude that argatroban is an effective inhibitor of thrombin bound t

51 nd is not approved in the United States; and argatroban is contraindicated in patients with impaired

52 84 (43.1%) had been treated first-line with argatroban, lepirudin, danaparoid, and fondaparinux, res

53 th the alternative nonheparin anticoagulants argatroban, lepirudin, or danaparoid.

54 29 patients (21.5%) received treatment with argatroban, lepirudin, or fondaparinux: 10 of 10 heparin

55 a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen

56 and adverse events averted compared with IV argatroban or bivalirudin infusions.

57 onset, adjunctive treatment with intravenous argatroban or eptifibatide did not reduce poststroke dis

58 d clinical trial reveal that the addition of argatroban or eptifibatide to intravenous thrombolysis w

59 hin 6 h were randomized to heparin, low-dose argatroban or high-dose argatroban in addition to TPA.

60 arin with a direct thrombin inhibitor (e.g., argatroban or lepirudin) or the heparinoid danaparoid (w

61 First-line therapies for HIT are argatroban or lepirudin.

62 Patients were randomized to placebo, argatroban, or eptifibatide within 75 minutes of intrave

63 d with normal saline (control), bivalirudin, argatroban, or heparin and outcomes were assessed on pos

64 ieved in 42.1% of heparin, 56.8% of low-dose argatroban (p = 0.20 vs. heparin) and 58.7% of high-dose

65 p = 0.20 vs. heparin) and 58.7% of high-dose argatroban patients (p = 0.13 vs. heparin).

66 f low-dose argatroban and 25.5% of high-dose argatroban patients (p = 0.23).

67 d in 2.6% and 4.3% of low-dose and high-dose argatroban patients, respectively.

68 d lung volume in vivo, while bivalirudin and argatroban preserved lung growth.

69 Argatroban reduced both alpha-smooth muscle actin expres

70 Argatroban reduced serum triglyceride and cholesterol le

71 ed cognitive deficit, whereas rats receiving argatroban retained intact learning and memory.

72 tissue-type plasminogen activator (tPA), on argatroban's ability to inhibit thrombin.

73 In contrast, argatroban showed no effect on procoagulant platelets an

74 creased the available thrombin activity, yet argatroban still inhibited this clot-associated thrombin

75 Argatroban therapy vs. control significantly reduces the

76 Argatroban therapy, relative to control subjects, also s

77 Argatroban-treated patients achieved therapeutic activat

78 tio, 4.10; 95% CI, 1.12-15.01; p =.033), and argatroban-treated patients had significantly reduced od

79 new thrombosis, was reduced significantly in argatroban-treated patients versus control subjects with

80 In HITTS, the composite incidence in argatroban-treated patients was 43.8% versus 56.5% in co

81 s with heparin-induced thrombocytopenia (767 argatroban-treated patients, 193 historical controls).

82 analysis of the composite end point favored argatroban treatment in HIT (P=0.010) and HITTS (P=0.014

83 was significantly more frequent in high-dose argatroban versus heparin patients: 57.1% versus 20.0% (

84 The posterior probability that argatroban was better than placebo was 0.002 (posterior

85 The Hill coefficient for argatroban was the lowest, at 1.7 +/- 0.2 (95% confidenc

86 all molecule active site inhibitors, such as argatroban, were the observation that fibrinopeptide A h

87 ns of heparin, danaparoid, fondaparinux, and argatroban with VITT-Ab/PF4 complexes using an ex vivo m